PriceTargets.com logo

Owens & Minor - OMI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.29
  • Forecasted Upside: -6.05%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$24.79 As of 04/19/2024 01:00 AM ET
▲ +0.73 (3.03%)

This chart shows the closing price for OMI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Owens & Minor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMI

Analyst Price Target is $23.29
▼ -6.05% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Owens & Minor in the last 3 months. The average price target is $23.29, with a high forecast of $28.00 and a low forecast of $19.00. The average price target represents a -6.05% upside from the last price of $24.79.

This chart shows the closing price for OMI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 8 investment analysts is to hold stock in Owens & Minor. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$24.00 ➝ $28.00Low
2/26/2024Leerink PartnrsReiterated RatingMarket PerformLow
2/26/2024SVB LeerinkInitiated CoverageMarket Perform$24.00Low
2/21/2024CitigroupBoost TargetNeutral ➝ Neutral$23.00 ➝ $24.00Low
2/21/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$21.00 ➝ $23.00Low
1/29/2024UBS GroupLower TargetBuy ➝ Buy$28.00 ➝ $26.00Low
1/3/2024BarclaysInitiated CoverageEqual Weight$21.00Low
12/8/2023UBS GroupBoost TargetBuy ➝ Buy$22.00 ➝ $28.00Low
11/17/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$21.00 ➝ $19.00Low
8/8/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$18.00 ➝ $19.00Low
8/4/2023CitigroupLower Target$23.00 ➝ $21.00Low
5/8/2023UBS GroupBoost Target$22.00 ➝ $24.00Low
5/8/2023Robert W. BairdBoost Target$18.00 ➝ $21.00Low
3/8/2023CitigroupLower TargetNeutral$20.00 ➝ $17.00Low
3/7/2023Credit Suisse GroupLower TargetNeutral$20.00 ➝ $17.00Low
3/1/2023Robert W. BairdLower TargetNeutral$23.00 ➝ $18.00Low
11/3/2022CitigroupBoost TargetNeutral$18.00 ➝ $20.00Low
10/14/2022Credit Suisse GroupLower TargetHold Neutral$37.00 ➝ $20.00Low
10/13/2022CitigroupDowngradeBuy ➝ Neutral$52.00 ➝ $18.00Low
10/12/2022Bank Of America (Bofa)DowngradeBuy ➝ Underperform$43.00 ➝ $17.00Low
10/12/2022Bank of AmericaDowngradeBuy ➝ Underperform$43.00 ➝ $17.00Low
10/12/2022Robert W. BairdDowngradeOutperform ➝ Neutral$62.00 ➝ $22.00Low
8/4/2022Credit Suisse GroupLower TargetNeutral$43.00 ➝ $37.00Low
8/4/2022Robert W. BairdLower TargetOutperform$70.00 ➝ $62.00N/A
8/4/2022CitigroupLower Target$58.00 ➝ $52.00Low
5/16/2022CitigroupBoost TargetNA$58.00N/A
4/26/2022CitigroupInitiated CoverageBuyHigh
2/28/2022Credit Suisse GroupBoost TargetNeutral$42.00 ➝ $43.00Medium
12/17/2021CitigroupUpgradeNeutral ➝ Buy$55.00Low
8/4/2021Credit Suisse GroupLower TargetNeutral$43.00 ➝ $42.00High
5/27/2021Robert W. BairdBoost TargetBuy ➝ Outperform$52.00 ➝ $55.00Medium
5/27/2021CitigroupBoost TargetNeutral$39.00 ➝ $46.00Medium
5/11/2021Credit Suisse GroupBoost TargetNeutral$34.00 ➝ $38.00Medium
3/26/2021Robert W. BairdUpgradeOutperform$45.00 ➝ $50.00High
2/25/2021BarclaysBoost TargetEqual Weight$23.00 ➝ $33.00High
12/17/2020UBS GroupUpgradeNeutral ➝ Buy$27.00 ➝ $37.00Medium
12/11/2020Smith Barney CitigroupInitiated CoverageNeutral$30.00Low
11/5/2020UBS GroupBoost TargetNeutral$13.00 ➝ $27.00High
11/4/2020BarclaysBoost TargetEqual Weight$20.00 ➝ $23.00High
9/25/2020CSFBBoost TargetNeutral$18.00 ➝ $22.00Low
9/25/2020Credit Suisse GroupBoost TargetNeutral$18.00 ➝ $22.00Medium
9/25/2020BarclaysUpgradeUnderweight ➝ Equal Weight$20.00Low
9/24/2020Robert W. BairdBoost TargetOutperform$21.00 ➝ $34.00High
8/7/2020Credit Suisse GroupLower TargetNeutral$17.00 ➝ $16.00Low
7/22/2020BarclaysBoost TargetUnderweight$4.00 ➝ $10.00High
7/21/2020Robert W. BairdUpgradeNeutral ➝ Outperform$8.00 ➝ $14.00High
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$8.00 ➝ $12.00High
6/10/2020CfraBoost TargetBuy$8.50 ➝ $9.50High
5/7/2020CfraLower TargetBuy$11.00 ➝ $8.50Low
5/5/2020Robert W. BairdDowngradeOutperform ➝ Neutral$8.00High
4/22/2020Credit Suisse GroupInitiated CoverageNeutral$8.00Low
3/30/2020CfraUpgradeHold ➝ Buy$5.50 ➝ $9.00High
1/21/2020Robert W. BairdUpgradeNeutral ➝ Outperform$9.00High
9/6/2019Bank of AmericaBoost TargetNeutral$4.00 ➝ $7.50Medium
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 16 very positive mentions
  • 24 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/20/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Owens & Minor logo
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.
Read More

Today's Range

Now: $24.79
Low: $24.07
High: $24.81

50 Day Range

MA: $24.90
Low: $21.09
High: $27.95

52 Week Range

Now: $24.79
Low: $13.34
High: $28.35

Volume

319,861 shs

Average Volume

642,993 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Owens & Minor?

The following Wall Street analysts have issued research reports on Owens & Minor in the last twelve months: Barclays PLC, Citigroup Inc., Credit Suisse Group AG, JPMorgan Chase & Co., Leerink Partnrs, Robert W. Baird, StockNews.com, SVB Leerink LLC, TheStreet, and UBS Group AG.
View the latest analyst ratings for OMI.

What is the current price target for Owens & Minor?

7 Wall Street analysts have set twelve-month price targets for Owens & Minor in the last year. Their average twelve-month price target is $23.29, suggesting a possible downside of 6.0%. Robert W. Baird has the highest price target set, predicting OMI will reach $28.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $19.00 for Owens & Minor in the next year.
View the latest price targets for OMI.

What is the current consensus analyst rating for Owens & Minor?

Owens & Minor currently has 1 sell rating, 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OMI, but not buy more shares or sell existing shares.
View the latest ratings for OMI.

What other companies compete with Owens & Minor?

Other companies that are similar to Owens & Minor include Patterson Companies, Avidity Biosciences, PTC Therapeutics, Galapagos and Sana Biotechnology. Learn More about companies similar to Owens & Minor.

How do I contact Owens & Minor's investor relations team?

Owens & Minor's physical mailing address is 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA, 23261. The company's listed phone number is (804) 723-7000 and its investor relations email address is [email protected]. The official website for Owens & Minor is www.owens-minor.com. Learn More about contacing Owens & Minor investor relations.